Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update

Author's Avatar
Feb 13, 2023
  • Data announced from two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors
  • Entered into collaboration with Janssen Biotech for the evaluation of three Sonnet pipeline compounds
  • Successfully completed two IND-enabling toxicology studies with SON-1210 in non-human primate